On Friday, Syndax Pharmaceuticals Inc (NASDAQ: SNDX) opened lower -9.71% from the last session, before settling in for the closing price of $12.46. Price fluctuations for SNDX have ranged from $11.62 to $25.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 1801.91% over the last five years. Company’s average yearly earnings per share was noted -3.14% at the time writing. With a float of $84.17 million, this company’s outstanding shares have now reached $85.69 million.
The firm has a total of 270 workers. Let’s measure their productivity. In terms of profitability, gross margin is -87.26%, operating margin of -1434.43%, and the pretax margin is -1346.11%.
Syndax Pharmaceuticals Inc (SNDX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Syndax Pharmaceuticals Inc is 2.18%, while institutional ownership is 111.92%. The most recent insider transaction that took place on Mar 04 ’25, was worth 117,564. In this transaction Chief Executive Officer of this company sold 7,814 shares at a rate of $15.05, taking the stock ownership to the 300,121 shares. Before that another transaction happened on Mar 04 ’25, when Company’s Officer proposed sale 13,888 for $15.48, making the entire transaction worth $214,986.
Syndax Pharmaceuticals Inc (SNDX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -3.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.23% during the next five years compared to -15.16% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Check out the current performance indicators for Syndax Pharmaceuticals Inc (SNDX). In the past quarter, the stock posted a quick ratio of 5.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 40.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.73, a number that is poised to hit -1.24 in the next quarter and is forecasted to reach -2.80 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Analysing the last 5-days average volume posted by the [Syndax Pharmaceuticals Inc, SNDX], we can find that recorded value of 2.1 million was lower than the volume posted last year of 2.1 million. As of the previous 9 days, the stock’s Stochastic %D was 30.66%. Additionally, its Average True Range was 0.84.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 1.40%, which indicates a significant decrease from 5.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.22% in the past 14 days, which was higher than the 70.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.11, while its 200-day Moving Average is $17.35. Now, the first resistance to watch is $11.92. This is followed by the second major resistance level at $12.58. The third major resistance level sits at $13.00. If the price goes on to break the first support level at $10.84, it is likely to go to the next support level at $10.42. Should the price break the second support level, the third support level stands at $9.76.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
There are currently 86,044K shares outstanding in the company with a market cap of 968.00 million. Presently, the company’s annual sales total 23,680 K according to its annual income of -318,760 K. Last quarter, the company’s sales amounted to 7,680 K and its income totaled -94,170 K.
